Responses
Treatments
Original article
Does a mandatory non-medical switch from originator to biosimilar infliximab lead to increased use of outpatient healthcare resources? A register-based study in patients with inflammatory arthritis
Compose a Response to This Article
Other responses
No responses have been published for this article.